ENZN Enzon Pharmaceuticals Inc

  1. Stocks
  2. Healthcare
  3. OTC: ENZN

Price (delayed)

$0.65

Market cap

$48.24M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.03

Enterprise value

$97,492

Sector: Healthcare
Industry: Biotechnology
Website: http://enzon.com/

Highlights

The equity has grown by 42% from the previous quarter and by 22% YoY
The gross profit has plunged by 75% YoY and by 22% from the previous quarter
ENZN's revenue has dropped by 75% year-on-year and by 22% since the previous quarter

Key stats

What are the main financial stats of ENZN
Market
Shares outstanding
74.21M
Market cap
$48.24M
Enterprise value
$97,492
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
3.9
Price to sales (P/S)
638.75
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.87
Earnings
Revenue
$52,000
EBIT
-$1.3M
EBITDA
-$1.3M
Free cash flow
-$380,000
Per share
EPS
-$0.03
Free cash flow per share
-$0.01
Book value per share
$0.17
Revenue per share
$0
TBVPS
$0.94
Balance sheet
Total assets
$48.23M
Total liabilities
$40.87M
Debt
$0
Equity
$7.36M
Working capital
$47.82M
Liquidity
Debt to equity
0
Current ratio
117.07
Quick ratio
116.92
Net debt/EBITDA
36.92
Margins
EBITDA margin
-2,507.7%
Gross margin
100%
Net margin
-2,521.2%
Operating margin
-2,509.6%
Efficiency
Return on assets
-10.7%
Return on equity
-29.6%
Return on invested capital
N/A
Return on capital employed
-2.7%
Return on sales
-2,507.7%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ENZN stock price

How has the Enzon Pharmaceuticals stock price performed over time
Intraday
0%
1 week
1.56%
1 month
51.16%
1 year
225%
YTD
160%
QTD
160%

Financial performance

How have Enzon Pharmaceuticals's revenue and profit performed over time
Revenue
$52,000
Gross profit
$52,000
Operating income
-$1.31M
Net income
-$1.31M
Gross margin
100%
Net margin
-2,521.2%
The gross profit has plunged by 75% YoY and by 22% from the previous quarter
ENZN's revenue has dropped by 75% year-on-year and by 22% since the previous quarter
ENZN's operating margin is down by 47% from the previous quarter
ENZN's net margin is down by 47% since the previous quarter

Growth

What is Enzon Pharmaceuticals's growth rate over time

Valuation

What is Enzon Pharmaceuticals stock price valuation
P/E
N/A
P/B
3.9
P/S
638.75
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.87
The company's EPS has shrunk by 50% YoY
The stock's price to book (P/B) is 179% more than its last 4 quarters average of 1.4
The equity has grown by 42% from the previous quarter and by 22% YoY
ENZN's revenue has dropped by 75% year-on-year and by 22% since the previous quarter

Efficiency

How efficient is Enzon Pharmaceuticals business performance
Enzon Pharmaceuticals's return on equity has shrunk by 174% YoY and by 46% QoQ
The company's return on sales fell by 47% QoQ
ENZN's return on assets is up by 43% since the previous quarter but it is down by 19% year-on-year

Dividends

What is ENZN's dividend history
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
Recent dividends

Financial health

How did Enzon Pharmaceuticals financials performed over time
Enzon Pharmaceuticals's total assets is 18% more than its total liabilities
ENZN's debt is 100% smaller than its equity
The equity has grown by 42% from the previous quarter and by 22% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.